Technical Analysis for ICVX - Icosavax, Inc.

Grade Last Price % Change Price Change
F 15.58 1.43% 0.22
ICVX closed down 6.97 percent on Tuesday, January 18, 2022, on 37 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. The bears made the stock sink to a new 52-week low. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong N/A Down Down
Historical ICVX trend table...

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish 1.43%
180 Bearish Setup Bearish Swing Setup 1.43%
NR7 Range Contraction 1.43%
New 52 Week Low Weakness 1.43%
Wide Bands Range Expansion 1.43%
Oversold Stochastic Weakness 1.43%
Lower Bollinger Band Walk Weakness -5.63%
New 52 Week Low Weakness -5.63%
Wide Bands Range Expansion -5.63%
Lower Bollinger Band Touch Weakness -5.63%
Older End-of-Day Signals for ICVX ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Lower Bollinger Band Support about 2 hours ago
Bearish 180 Entry about 2 hours ago
Fell Below Previous Day's Low about 2 hours ago
Down 2 % about 2 hours ago
Down 1% about 2 hours ago
View Earlier Intraday Alerts

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases. The company, with the help of its virus-like particle (VLP) platform technology, focuses primarily on life-threatening respiratory diseases. Its products in pipeline include IVX-A12, an respiratory syncytial virus (RSV) monovalent antigen candidate with RSV/human metapneumovirus (hMPV) bivalent target indication; IVX-121, a vaccine candidate with RSV target; IVX-241, a vaccine candidate with hMPV target; IVX-411, an original receptor binding domain (RBD) sequence antigen with SARS-CoV-2^ target indication; and IVX-421, a variant RBD antigen with SARS-CoV-2^ target indication. The company was incorporated in 2017 and is headquartered in Seattle, Washington.
Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Infectious Diseases Platform Technology Respiratory Diseases Severe Acute Respiratory Syndrome Coronavirus 2

Is ICVX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 49.99
52 Week Low 15.3114
Average Volume 91,968
200-Day Moving Average 0.00
50-Day Moving Average 22.98
20-Day Moving Average 20.37
10-Day Moving Average 17.99
Average True Range 1.92
ADX 36.24
+DI 7.61
-DI 30.55
Chandelier Exit (Long, 3 ATRs) 19.89
Chandelier Exit (Short, 3 ATRs) 21.07
Upper Bollinger Bands 25.67
Lower Bollinger Band 15.07
Percent B (%b) 0.03
BandWidth 52.00
MACD Line -2.01
MACD Signal Line -1.57
MACD Histogram -0.4457
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 16.85
Resistance 3 (R3) 17.00 16.65 16.60
Resistance 2 (R2) 16.65 16.27 16.58 16.52
Resistance 1 (R1) 16.01 16.04 15.83 15.86 16.44
Pivot Point 15.66 15.66 15.57 15.58 15.66
Support 1 (S1) 15.01 15.28 14.84 14.86 14.28
Support 2 (S2) 14.67 15.04 14.59 14.20
Support 3 (S3) 14.02 14.67 14.12
Support 4 (S4) 13.87